Life In The Old Dog Yet: Growth In Dyslipidemia Market Expected To 2025
Despite the further genericization of statins and ezetimibe, the arrival of expensive new therapies means the dyslipidemia market is still set for growth over the next eight years, say analysts from Datamonitor Healthcare.
You may also be interested in...
Novo Nordisk is making good on its strategy to prioritize the cardiovascular sector. Its latest deal sees the Danish pharma invest in Staten Biotechnology’s hypertriglyceridemia asset, with potential to acquire the company.
The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.
Updated ORION-1 data presented at the European Society of Cardiology have encouraged The Medicines Company to take an "aggressive" approach to its Phase III plans for the novel PCSK9 synthesis inhibitor.